--- title: "Weekly Recap | Tempus AI -9.86%, most brokers rate it buy" type: "News" locale: "en" url: "https://longbridge.com/en/news/300855206.md" description: "Tempus AI fell 9.86% this week to close at $76.63, underperforming the S&P 500 by roughly 9.59 percentage points. The stock opened the week higher and briefly touched $89.09 before pulling back over three consecutive sessions. Thursday saw a single-day drop of about 6.6%, and Friday held within a $75.80 to $80.305 range. Weekly amplitude reached 15.9%, while average daily volume of around 6.0m shares ran about 7.4% above the 60-day median, pointing to wider disagreement among traders." datetime: "2026-10-03T08:37:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/300855206.md) - [en](https://longbridge.com/en/news/300855206.md) - [zh-HK](https://longbridge.com/zh-HK/news/300855206.md) generator: "portal-rs" --- # Weekly Recap | Tempus AI -9.86%, most brokers rate it buy ## The Week Tempus AI fell 9.86% this week to close at $76.63, underperforming the S&P 500 by roughly 9.59 percentage points. The stock opened the week higher and briefly touched $89.09 before pulling back over three consecutive sessions. Thursday saw a single-day drop of about 6.6%, and Friday held within a $75.80 to $80.305 range. Weekly amplitude reached 15.9%, while average daily volume of around 6.0m shares ran about 7.4% above the 60-day median, pointing to wider disagreement among traders. ## Key Events The company-specific story this week centred on a regulatory approval and academic visibility. On Monday evening, Tempus AI announced FDA clearance for its ECG-MR tool, designed to flag undiagnosed mitral regurgitation. On Thursday, the company said 13 abstracts had been accepted for presentation at the European Society for Medical Oncology Congress 2026. A filing on the same day showed Diagnostics CEO Thomas Edward Schoenherr disposed of roughly $873,885 worth of common shares. Over the weekend an S-4/A registration statement was submitted, a routine securities-related disclosure. No earnings or major partnership news landed during the week, leaving the pullback tied largely to broader pressure on high-multiple growth names. ## Analyst Ratings Among the 20 firms covering the stock, 8 rate it buy, 2 rate it overweight, 9 rate it hold, and 1 rates it sell. The consensus rating is buy, with a consensus target of $70.05556, about 8.58% below the latest price. The target range is wide, from $35 to $100, indicating a meaningful split in valuation views. Tempus ranks 8th within a group of 54 life science tools and services companies. The rating mix leans constructive, but a target below spot shows how divided analysts are on how much premium the stock should carry. ## The Week Ahead No company earnings are scheduled for next week. On Monday the US S&P Global services PMI final and ISM non-manufacturing PMI will be released; Tuesday brings international trade data; Wednesday has EIA crude inventory figures. These releases could shift discount-rate expectations for growth stocks at a time when risk appetite has already retreated. Whether sentiment stabilises or extends the pullback is the main thing to watch. ## In Short Tempus AI recorded a near double-digit weekly decline despite an FDA clearance and ESMO academic presence, which suggests the market is trimming its appetite for richly valued growth names. The rating structure is mixed: 10 firms at buy or overweight against 9 at hold. The latest daily capital snapshot shows the heaviest outflow on the small-lot side, with large-lot inflow and outflow nearly matched. The valuation remains stretched at 30.90x P/B and negative P/E, leaving the shares highly sensitive to shifts in sentiment and discount rates. The key question is whether upcoming macro data stabilises growth-stock pricing and whether Tempus can convert its regulatory and academic wins into sustained revenue growth. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [TEM.US](https://longbridge.com/en/quote/TEM.US.md) ## Related News & Research - [Tempus AI Expands Oncology Data Partnership With Bristol Myers Squibb Through 2031](https://longbridge.com/en/news/302883335.md) - [Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development](https://longbridge.com/en/news/302882838.md) - [AI fever ignites a boom in thematic ETFs as fund managers hunt for their next big hit](https://longbridge.com/en/news/302963080.md) - [15,817 Shares of C.H. Robinson Worldwide, Inc. $CHRW Bought by Capital City Trust Co. FL](https://longbridge.com/en/news/302957324.md) - [MRNA: Intismeran plus pembrolizumab improved RFS and DMFS in resected melanoma](https://longbridge.com/en/news/302972013.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**